FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
haura nor raananaa	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_	7														
1. Name and Address of Reporting Person* ZUERBLIS KENNETH J				ENZ	2. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS INC [ENZN]									tionship of Reporting all applicable) Director		ıg Pe	10% O	wner		
(Loot) (First) (Midel-)						-								X	Office	r (give title		Other (specify below)		
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 02/06/2004									Chief Financial Officer					
C/O ENZON PHARMACEUTICALS, INC.						02,00,200							_			- Inter i inter	TCTGT	Officer		
685 ROUTE 202/206						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)														X Form filed by One Reporting Person					on	
BRIDGEWATER NJ 08807													Form filed by More than One Reporting Person							
(City)	(St	ate) (Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Execution [Code (Ins	Transaction Disp		ecurities Acquired osed Of (D) (Instr. 5)		4 S	Securities Beneficially Owned		Forr (D) o	n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amoun	mount (A) or (D)		e F	Report Fransa	llowing ported ansaction(s) str. 3 and 4)		tr. 4)	(Instr. 4)			
		Ta	able II						uired, Dis						/ned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/		4. Transaction Code (Instr. 8)		n of l		6. Date Exercisable Expiration Date (Month/Day/Year)			e and 7. Title and Amount of Securities Underlying Derivative Security (Instrand 4)		of Deri	. Price if Derivative Security Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
					Code	v	(A)	(D)	Date Exercisable		iration e	Title	Amount or Number of Shares							
Employee Stock Option (Right To Buy) ⁽¹⁾	\$14.15	02/06/2004			A		50,000		(2)	02/0	06/2014	Common Stock	50,000)	5 0	50,000		D		
Restricted Stock Unit ⁽³⁾	\$0	02/06/2004			A		12,500		(4)		(4)	Common Stock	12,500)	5 0	12,500		D		

Explanation of Responses:

- 1. Employee stock option granted by Enzon Pharmaceuticals, Inc. ("Enzon") pursuant to Enzon's 2001 Incentive Stock Plan and qualified under Rule 16b-3(d).
- 2. The option vests in four equal annual installments beginning on February 6, 2005.
- 3. Restricted stock units granted by Enzon pursuant to Enzon's 2001 Incentive Stock Plan and qualified under Rule 16b-3(d).
- 4. Of the 12,500 units granted, 3,750 will vest on February 6, 2007, 3,750 will vest on February 6, 2008 and the remaining 5,000 will vest on February 6, 2009.

/s/ Kenneth J. Zuerblis 02/10/2004

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.